Annual report pursuant to Section 13 and 15(d)

Shareholders' Equity - Schedule of Warrants Outstanding and Exercisable (Details)

v3.19.3.a.u2
Shareholders' Equity - Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Warrant Outstanding Exercise Price   $ 1.74
Warrants Outstanding 26,538,593  
Warrants exercisable 26,538,593  
Range One [Member]    
Warrant Outstanding Exercise Price $ 3.10  
Warrants Outstanding 48,387  
Warrants exercisable 48,387  
Expiration Date Sep. 19, 2022  
Range Two [Member]    
Warrant Outstanding Exercise Price $ 3.10  
Warrants Outstanding 462,106  
Warrants exercisable 462,106  
Expiration Date May 10, 2024  
Range Three [Member]    
Warrant Outstanding Exercise Price $ 3.10  
Warrants Outstanding 602,414  
Warrants exercisable 602,414  
Expiration Date Jul. 25, 2024  
Range Four [Member]    
Warrant Outstanding Exercise Price $ 3.10  
Warrants Outstanding 1,064,518  
Warrants exercisable 1,064,518  
Expiration Date Nov. 08, 2024  
Range Five [Member]    
Warrant Outstanding Exercise Price $ 2.00  
Warrants Outstanding 900,000  
Warrants exercisable 900,000  
Expiration Date Apr. 10, 2023  
Range Six [Member]    
Warrant Outstanding Exercise Price $ 1.00  
Warrants Outstanding 4,294,500  
Warrants exercisable 4,294,500  
Expiration Date Jul. 17, 2025  
Range Seven [Member]    
Warrant Outstanding Exercise Price $ 0.75  
Warrants Outstanding 9,583,334  
Warrants exercisable 9,583,334  
Expiration Date [1] Sep. 25, 2020  
Range Eight [Member]    
Warrant Outstanding Exercise Price $ 0.90  
Warrants Outstanding 9,583,334  
Warrants exercisable 9,583,334  
Expiration Date Mar. 25, 2024  
[1] Subject to termination prior to the indicated date following the Company's release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013 plus twenty-one (21) trading days.